» Articles » PMID: 27967300

Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review

Overview
Specialty Endocrinology
Date 2016 Dec 15
PMID 27967300
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Lipodystrophy syndromes are characterized by generalized or partial absence of adipose tissue.

Objective: We conducted a systematic review to synthesize data on clinical and metabolic features of lipodystrophy (age at onset, < 18 years).

Data Source: Sources included Medline, Embase, Cochrane Library, Scopus and Non-Indexed Citations from inception through January 2016.

Study Selection: Search terms included lipodystrophy, and age 0 to 18 years. Patients with unambiguous diagnosis of lipodystrophy were included. Lipodystrophy secondary to HIV treatment was excluded.

Data Synthesis: We identified 1141 patients from 351 studies. Generalized fat loss involving face, neck, abdomen, thorax, and upper and lower limbs was explicitly reported in 65% to 93% of patients with congenital generalized lipodystrophy (CGL) and acquired generalized lipodystrophy (AGL). In familial partial lipodystrophy (FPL), fat loss occurred from upper and lower limbs, with sparing of face and neck. In acquired partial lipodystrophy (APL), upper limbs were involved while lower limbs were spared. Other features were prominent musculature, acromegaloid, acanthosis nigricans and hepatosplenomegaly. Diabetes mellitus was diagnosed in 48% (n = 222) of patients with CGL (mean age at onset, 5.3 years). Hypertriglyceridemia was observed in CGL, AGL and FPL. Multiple interventions were used, with most patients receiving ≥ 3 interventions and being ≥ 18 years of age at the initiation of interventions.

Conclusions: To our knowledge, this is the largest reported pooled database describing lipodystrophy patients with age at onset < 18 years. We have suggested core and supportive clinical features and summarized data on available interventions, outcomes and mortality.

Citing Articles

Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.

Patni N, Chard C, Araujo-Vilar D, Phillips H, Magee D, Akinci B Orphanet J Rare Dis. 2024; 19(1):263.

PMID: 38992753 PMC: 11241872. DOI: 10.1186/s13023-024-03245-3.


Analysis of disease characteristics of a large patient cohort with congenital generalized lipodystrophy from the Middle East and North Africa.

Al Yaarubi S, Alsagheir A, Al Shidhani A, Alzelaye S, Alghazir N, Brema I Orphanet J Rare Dis. 2024; 19(1):118.

PMID: 38481246 PMC: 10935864. DOI: 10.1186/s13023-024-03084-2.


A retrospective study on side effects of first-line antiretroviral drugs on HIV patients based on 1A, 2A, and 5A regimen records at Zomba Central Hospital, Malawi.

Sindie R, Mwakilama E, Chizala P, Namangale J Afr Health Sci. 2024; 23(3):468-480.

PMID: 38357124 PMC: 10862583. DOI: 10.4314/ahs.v23i3.54.


Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain.

Fernandez-Pombo A, Sanchez-Iglesias S, Castro-Pais A, Ginzo-Villamayor M, Cobelo-Gomez S, Prado-Morana T Front Endocrinol (Lausanne). 2023; 14:1250203.

PMID: 38034001 PMC: 10687442. DOI: 10.3389/fendo.2023.1250203.


Unusual magnetic resonance imaging findings of cystic bone lesions in congenital generalized lipodystrophy.

T de Oliveira T, C Natal M, Teixeira A, Machado B J Postgrad Med. 2022; 68(4):236-238.

PMID: 36348607 PMC: 9841538. DOI: 10.4103/jpgm.jpgm_1031_21.


References
1.
Gandhi G, Murad M, Fujiyoshi A, Mullan R, Flynn D, Elamin M . Patient-important outcomes in registered diabetes trials. JAMA. 2008; 299(21):2543-9. DOI: 10.1001/jama.299.21.2543. View

2.
Eisinger A, Shortland J, Moorhead P . Renal disease in partial lipodystrophy. Q J Med. 1972; 41(163):343-54. View

3.
Aotani D, Ebihara K, Sawamoto N, Kusakabe T, Aizawa-Abe M, Kataoka S . Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy. J Clin Endocrinol Metab. 2012; 97(10):3663-71. PMC: 3462942. DOI: 10.1210/jc.2012-1872. View

4.
Boschmann M, Engeli S, Moro C, Luedtke A, Adams F, Gorzelniak K . LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance. J Clin Endocrinol Metab. 2010; 95(4):1634-43. PMC: 2853996. DOI: 10.1210/jc.2009-1293. View

5.
Prasad N, Reddy P, Menon B, Karthik T, Ahmed F, Chakravarthy M . Recurrent stroke as a presenting feature of acquired partial lipodystrophy. Indian J Endocrinol Metab. 2013; 16(Suppl 2):S455-7. PMC: 3603113. DOI: 10.4103/2230-8210.104130. View